Sign in to fuzzto save your conversations, follow your research and come back anytime.
Kopran
KOPRAN
NSE
BSE
NSEBSESectorHealthcare
232.24
Loading chart…
NSEBSEThe Quarter story
The two most recent quarterly results, compared side-by-side.
Kopran Ltd shows strong recovery in key API segments and export markets, though consolidated revenue and profitability face seasonal volatility.
Carbapenem revenue grows from ₹3,612 Cr in Q1 FY26 to ₹4,488 Cr in Q1 FY27, signaling major product cycle recovery.
Consolidated revenue eases from ₹13,522 Cr in Q1 FY26 to ₹15,605 Cr in Q1 FY27, reflecting seasonal sales cycles.
Macrolide revenue expands from ₹52 Cr in Q1 FY26 to ₹2,230 Cr in Q1 FY27, confirming strong therapeutic segment momentum.
Formulations sales settle from ₹5,078 Cr in Q1 FY26 to ₹5,709 Cr in Q1 FY27, indicating predictable quarterly ordering cycles.
Neuromodulator revenue rises from ₹31 Cr in Q2 FY26 to ₹1,024 Cr in Q1 FY27, signaling accelerating specialty drug adoption.
EBITDA moderates from ₹1,413 Cr in Q1 FY26 to ₹1,588 Cr in Q1 FY27, indicating seasonal profitability swings.
Export revenue recovers from ₹3,544 Cr in Q1 FY26 to ₹3,861 Cr in Q1 FY27, indicating resilient overseas demand.
Canada sales decline from ₹148 Cr in Q2 FY26 to ₹33 Cr in Q1 FY27, signaling weakening North American demand.
Forex impact improves from a loss of ₹824 Cr in Q2 FY26 to a gain of ₹198 Cr in Q1 FY27, signaling effective currency hedging.
Latem sales drop from ₹216 Cr in Q1 FY26 to ₹0.60 Cr in Q1 FY27, reflecting severe regional market contraction.